Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis-Reference-Cited by-同舟云学术

Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis

Published:2023-10 Issue:10 Volume:11 Page:e1648-e1657
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Phillips Andrew N,Bansi-Matharu Loveleen,Shahmanesh Maryam,Hargreaves James R,Smith Jennifer,Revill Paul,Sibanda Euphemia,Ehrenkranz Peter,Sikwese Kenly,Rodger Alison,Lundgren Jens D,Gilks Charles F,Godfrey Catherine,Cowan Frances,Cambiano Valentina

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Oral preexposure prophylaxis continuation, measurement and reporting;Stankevitz;AIDS,2020

2. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa;Heffron;Gates Open Res,2018

3. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical trial (HPTN 076);Tolley;J Int AIDS Soc,2019

4. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial;Delany-Moretlwe;Lancet,2022

5. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study;Smith;Lancet HIV,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Occupational post‐exposure prophylaxis among healthcare workers: a scoping review of factors affecting optimal utilization;Journal of the International AIDS Society;2024-08

2. Unrestricted access to tenofovir, lamivudine, and dolutegravir as pre-exposure or post-exposure prophylaxis in community settings;The Lancet Global Health;2023-10